📢 Exciting news! Thrilled to share I will be taking on the role of AIMM’s Social Media Editor! Grateful for this opportunity and excited to foster connections in the digital space and engage with our path community. #onlineaheadofprint #IHCpath
🔗 journals.lww.com/appliedimmun...
🔗 journals.lww.com/appliedimmun...
February 5, 2025 at 11:30 AM
📢 Exciting news! Thrilled to share I will be taking on the role of AIMM’s Social Media Editor! Grateful for this opportunity and excited to foster connections in the digital space and engage with our path community. #onlineaheadofprint #IHCpath
🔗 journals.lww.com/appliedimmun...
🔗 journals.lww.com/appliedimmun...
Just published! Check out this latest article 👉🏻 HER2 amplification is rare (1.7%) in low-grade, tubule-forming breast cancers with 2+ HER2 IHC; findings suggest ISH may be unnecessary in this subset #breastpath #IHCpath #pathsky
The Value of Routine Reflex In Situ Hybridization Testing in Low-grade Tubule-forming Invasive Breast Cancers With Equivocal HER2 Immunohistochemistry - A Reappraisal of the ASCO/CAP Guidelines journals.lww.com/appliedimmun...
The Value of Routine Reflex In Situ Hybridization Testing... : Applied Immunohistochemistry & Molecular Morphology
emistry (IHC). While this recommendation mainly addresses aggressive tumor types such as micropapillary carcinoma, it is applied to low-grade, tubule-forming IBCs unlikely to show HER2 amplification. ...
journals.lww.com
May 29, 2025 at 12:44 AM
Just published! Check out this latest article 👉🏻 HER2 amplification is rare (1.7%) in low-grade, tubule-forming breast cancers with 2+ HER2 IHC; findings suggest ISH may be unnecessary in this subset #breastpath #IHCpath #pathsky
🚨Spoiler alert: Primary cutaneous NUT adnexal carcinoma can metastasize—but long-term outcomes remain unclear. We're about to report an almost 20-year follow-up on this new entity. Stay tuned! 😆🔬🧬
#dermpath #pathology #molpath #IHCPath #MDACCPath
#dermpath #pathology #molpath #IHCPath #MDACCPath
May 31, 2025 at 11:53 PM
🚨Spoiler alert: Primary cutaneous NUT adnexal carcinoma can metastasize—but long-term outcomes remain unclear. We're about to report an almost 20-year follow-up on this new entity. Stay tuned! 😆🔬🧬
#dermpath #pathology #molpath #IHCPath #MDACCPath
#dermpath #pathology #molpath #IHCPath #MDACCPath
🚨 Hot off the press! The most comprehensive open-access review of TRPS1 and its applications in #dermpath is now available. Everything you need to know, based on our 4+ years of experience, is in one place. Check it out! 😆🔬
www.jpatholtm.org/journal/view...
#MDACCPath #IHCPath #TRPS1
www.jpatholtm.org/journal/view...
#MDACCPath #IHCPath #TRPS1
January 30, 2026 at 1:42 AM
🚨 Hot off the press! The most comprehensive open-access review of TRPS1 and its applications in #dermpath is now available. Everything you need to know, based on our 4+ years of experience, is in one place. Check it out! 😆🔬
www.jpatholtm.org/journal/view...
#MDACCPath #IHCPath #TRPS1
www.jpatholtm.org/journal/view...
#MDACCPath #IHCPath #TRPS1
It’s been a while since I shared a case.
Did you know this immunoprofile, especially the diffuse TRPS1 immunoreactivity, strongly favors primary EMPD over secondary EMPD? Give it a try if you haven’t used it in your practice. 😆🔬
#dermpath #IHCPath #MDACCPath
Did you know this immunoprofile, especially the diffuse TRPS1 immunoreactivity, strongly favors primary EMPD over secondary EMPD? Give it a try if you haven’t used it in your practice. 😆🔬
#dermpath #IHCPath #MDACCPath
August 6, 2025 at 6:22 PM
It’s been a while since I shared a case.
Did you know this immunoprofile, especially the diffuse TRPS1 immunoreactivity, strongly favors primary EMPD over secondary EMPD? Give it a try if you haven’t used it in your practice. 😆🔬
#dermpath #IHCPath #MDACCPath
Did you know this immunoprofile, especially the diffuse TRPS1 immunoreactivity, strongly favors primary EMPD over secondary EMPD? Give it a try if you haven’t used it in your practice. 😆🔬
#dermpath #IHCPath #MDACCPath
Thursday #DermPath special! 😆🔬
Many tumors unfortunately can metastasize to the skin, including this one. 😫
Cutaneous metastasis of pancreatic adenocarcinoma showing complete loss of DPC4 expression.
#MDACCPath #pathology #GIpath #IHCpath
Many tumors unfortunately can metastasize to the skin, including this one. 😫
Cutaneous metastasis of pancreatic adenocarcinoma showing complete loss of DPC4 expression.
#MDACCPath #pathology #GIpath #IHCpath
December 12, 2024 at 9:51 PM
Thursday #DermPath special! 😆🔬
Many tumors unfortunately can metastasize to the skin, including this one. 😫
Cutaneous metastasis of pancreatic adenocarcinoma showing complete loss of DPC4 expression.
#MDACCPath #pathology #GIpath #IHCpath
Many tumors unfortunately can metastasize to the skin, including this one. 😫
Cutaneous metastasis of pancreatic adenocarcinoma showing complete loss of DPC4 expression.
#MDACCPath #pathology #GIpath #IHCpath
Just published! Check out this latest article!
🔵 PD-L1 expression showed high concordance between cores and full slides.
🔵 CD8+ T cell and CD68+ macrophage densities varied; cores underrepresented immune infiltrates.
@fabiotavora.bsky.social #IHCpath #lungcancer
🔵 PD-L1 expression showed high concordance between cores and full slides.
🔵 CD8+ T cell and CD68+ macrophage densities varied; cores underrepresented immune infiltrates.
@fabiotavora.bsky.social #IHCpath #lungcancer
June 5, 2025 at 5:12 PM
Just published! Check out this latest article!
🔵 PD-L1 expression showed high concordance between cores and full slides.
🔵 CD8+ T cell and CD68+ macrophage densities varied; cores underrepresented immune infiltrates.
@fabiotavora.bsky.social #IHCpath #lungcancer
🔵 PD-L1 expression showed high concordance between cores and full slides.
🔵 CD8+ T cell and CD68+ macrophage densities varied; cores underrepresented immune infiltrates.
@fabiotavora.bsky.social #IHCpath #lungcancer
It was almost a normal lymph node sample while #ROSE assessment, but...
▫️Epithelioid binucleated cell was too suspicious.
▫️Cytokeratin was positive on isolated cells.
▫️#CellBlock is always mandatory for #IHCPath.
▫️Medullary thyroid carcinoma Mx.
#HemePath #CytoPath #FNAFriday
▫️Epithelioid binucleated cell was too suspicious.
▫️Cytokeratin was positive on isolated cells.
▫️#CellBlock is always mandatory for #IHCPath.
▫️Medullary thyroid carcinoma Mx.
#HemePath #CytoPath #FNAFriday
March 28, 2025 at 2:26 PM
It was almost a normal lymph node sample while #ROSE assessment, but...
▫️Epithelioid binucleated cell was too suspicious.
▫️Cytokeratin was positive on isolated cells.
▫️#CellBlock is always mandatory for #IHCPath.
▫️Medullary thyroid carcinoma Mx.
#HemePath #CytoPath #FNAFriday
▫️Epithelioid binucleated cell was too suspicious.
▫️Cytokeratin was positive on isolated cells.
▫️#CellBlock is always mandatory for #IHCPath.
▫️Medullary thyroid carcinoma Mx.
#HemePath #CytoPath #FNAFriday
Follicular lymphoma grade 1-2 treated with Rituximab. New lesion, rule out high grade:
▫️Small to medium sized lymphocytes
▫️Isolated centroblasts
▫️No tingible body macrophages
▫️Cytospin: Bcl2 + Bcl6 + CD10, scatered CD3 & CD20 negative
#CytoPath #HemePath #IHCPath #FNAFriday
▫️Small to medium sized lymphocytes
▫️Isolated centroblasts
▫️No tingible body macrophages
▫️Cytospin: Bcl2 + Bcl6 + CD10, scatered CD3 & CD20 negative
#CytoPath #HemePath #IHCPath #FNAFriday
July 10, 2026 at 3:38 PM
Follicular lymphoma grade 1-2 treated with Rituximab. New lesion, rule out high grade:
▫️Small to medium sized lymphocytes
▫️Isolated centroblasts
▫️No tingible body macrophages
▫️Cytospin: Bcl2 + Bcl6 + CD10, scatered CD3 & CD20 negative
#CytoPath #HemePath #IHCPath #FNAFriday
▫️Small to medium sized lymphocytes
▫️Isolated centroblasts
▫️No tingible body macrophages
▫️Cytospin: Bcl2 + Bcl6 + CD10, scatered CD3 & CD20 negative
#CytoPath #HemePath #IHCPath #FNAFriday
Considering contaminants such as gastric epithelium when dealing with #IPMN at #ROSE 👀. Atypia can be mild. Try to find:
▫️High grade features
▫️Nuclear membrane irregularities
▫️Inflammation/necrosis
▫️Papillary or small groups
▫️#IHCPath S100p IMP3
#EUSFNA #FNAFriday #CytoPath
▫️High grade features
▫️Nuclear membrane irregularities
▫️Inflammation/necrosis
▫️Papillary or small groups
▫️#IHCPath S100p IMP3
#EUSFNA #FNAFriday #CytoPath
April 25, 2025 at 3:24 PM
Considering contaminants such as gastric epithelium when dealing with #IPMN at #ROSE 👀. Atypia can be mild. Try to find:
▫️High grade features
▫️Nuclear membrane irregularities
▫️Inflammation/necrosis
▫️Papillary or small groups
▫️#IHCPath S100p IMP3
#EUSFNA #FNAFriday #CytoPath
▫️High grade features
▫️Nuclear membrane irregularities
▫️Inflammation/necrosis
▫️Papillary or small groups
▫️#IHCPath S100p IMP3
#EUSFNA #FNAFriday #CytoPath
Telomerase Immunocytochemistry in Lymphocytes From Chronic Lymphocytic Leukemia
✨hTERT shows stronger nuclear staining in B-CLL cells vs. normal; linked to poor B-CLL prognosis #IHCpath #hemepath @katcollmd.bsky.social @ihc-guy.bsky.social
🔗 journals.lww.com/appliedimmun...
✨hTERT shows stronger nuclear staining in B-CLL cells vs. normal; linked to poor B-CLL prognosis #IHCpath #hemepath @katcollmd.bsky.social @ihc-guy.bsky.social
🔗 journals.lww.com/appliedimmun...
May 15, 2025 at 3:59 PM
Telomerase Immunocytochemistry in Lymphocytes From Chronic Lymphocytic Leukemia
✨hTERT shows stronger nuclear staining in B-CLL cells vs. normal; linked to poor B-CLL prognosis #IHCpath #hemepath @katcollmd.bsky.social @ihc-guy.bsky.social
🔗 journals.lww.com/appliedimmun...
✨hTERT shows stronger nuclear staining in B-CLL cells vs. normal; linked to poor B-CLL prognosis #IHCpath #hemepath @katcollmd.bsky.social @ihc-guy.bsky.social
🔗 journals.lww.com/appliedimmun...
If anyone has a confirmed case and is interested in expanding IHC studies on this topic with me, please feel free to reach out for collaboration. 😆🔬🧬
#pathology #dermpath #IHCpath #molepath
#pathology #dermpath #IHCpath #molepath
🚨 Hot off the press! My correspondence has been published in JCP, highlighting the importance of post-publication peer review. 😆🔬
The article is open access. Check it out if you love #dermpath & are interested in NUT adnexal carcinoma. #MDACCPath #pathology
onlinelibrary.wiley.com/doi/10.1111/...
The article is open access. Check it out if you love #dermpath & are interested in NUT adnexal carcinoma. #MDACCPath #pathology
onlinelibrary.wiley.com/doi/10.1111/...
Correspondence: Primary Cutaneous NUT Adnexal Carcinoma: A Case Report With Novel Clinical and Pathological Observations
Click on the article title to read more.
onlinelibrary.wiley.com
May 9, 2026 at 1:43 AM
If anyone has a confirmed case and is interested in expanding IHC studies on this topic with me, please feel free to reach out for collaboration. 😆🔬🧬
#pathology #dermpath #IHCpath #molepath
#pathology #dermpath #IHCpath #molepath
Want to maximize Merkel cell carcinoma detection in sentinel lymph nodes? Go with panCK + INSM1 or panCK + SOX11. CK20’s sensitivity is just too low; its expression can be absent in up to 24% of MCCs. Check it out if you love #dermpath and #IHCpath. 😆🔬
#MDACCPath
pubmed.ncbi.nlm.nih.gov/40505699/
#MDACCPath
pubmed.ncbi.nlm.nih.gov/40505699/
INSM1: A highly sensitive marker for primary and metastatic Merkel cell carcinoma, superior to SOX11, pancytokeratin, and CK20 - PubMed
Detection of Merkel cell carcinoma (MCC) micrometastases in sentinel lymph nodes (SLNs) often necessitates immunohistochemical studies like pancytokeratin (panCK) or CK20. However, panCK can label non-epithelial cells, particularly dendritic reticulum cells, complicating interpretation, while CK20 i …
pubmed.ncbi.nlm.nih.gov
March 11, 2026 at 1:57 PM
Want to maximize Merkel cell carcinoma detection in sentinel lymph nodes? Go with panCK + INSM1 or panCK + SOX11. CK20’s sensitivity is just too low; its expression can be absent in up to 24% of MCCs. Check it out if you love #dermpath and #IHCpath. 😆🔬
#MDACCPath
pubmed.ncbi.nlm.nih.gov/40505699/
#MDACCPath
pubmed.ncbi.nlm.nih.gov/40505699/
Lastly, when in doubt, read this most comprehensive review on TRPS1 #IHCPath, which incorporates our extensive experience with this marker over the past 4–5 years in #dermpath. Free access! 😆🔬
#MDACCPath
pubmed.ncbi.nlm.nih.gov/41605620/
#MDACCPath
pubmed.ncbi.nlm.nih.gov/41605620/
The evolving role of TRPS1 in dermatopathology: insights from the past 4 years - PubMed
Over the past 4 years, trichorhinophalangeal syndrome type 1 (TRPS1) has rapidly gained attention among practicing pathologists, with numerous studies emerging that both support and question its diagnostic utility. Initially regarded as a highly specific marker for tumors of mammary origin, TRPS1 is …
pubmed.ncbi.nlm.nih.gov
February 28, 2026 at 2:37 PM
Lastly, when in doubt, read this most comprehensive review on TRPS1 #IHCPath, which incorporates our extensive experience with this marker over the past 4–5 years in #dermpath. Free access! 😆🔬
#MDACCPath
pubmed.ncbi.nlm.nih.gov/41605620/
#MDACCPath
pubmed.ncbi.nlm.nih.gov/41605620/
Here is another study supporting the role of TRPS1 #IHCPath in MPDs/EMPDs, which my initial studies proposed 2–3 years ago. Despite the major pushback and rejection from the #dermpath community at the time, I am glad to see more and more studies confirming our initial impression. 😆🔬
TRPS1 Expression Across the Spectrum of Paget Disease and Morphologic Mimics journals.lww.com/appliedimmun...
journals.lww.com
February 28, 2026 at 2:31 PM
Shoutout to our amazing #MDACCPath #IHCPath team for making work fun! 😆🔬🎨🎉
We had an Easter egg hunt in the lab, and I got to decorate my microscope with the treasures I found. Wishing everyone a joyful Easter weekend! 🐣🪺
#pathology
We had an Easter egg hunt in the lab, and I got to decorate my microscope with the treasures I found. Wishing everyone a joyful Easter weekend! 🐣🪺
#pathology
April 18, 2025 at 10:48 PM
Shoutout to our amazing #MDACCPath #IHCPath team for making work fun! 😆🔬🎨🎉
We had an Easter egg hunt in the lab, and I got to decorate my microscope with the treasures I found. Wishing everyone a joyful Easter weekend! 🐣🪺
#pathology
We had an Easter egg hunt in the lab, and I got to decorate my microscope with the treasures I found. Wishing everyone a joyful Easter weekend! 🐣🪺
#pathology
New Year #dermpath special! 😆🔬
What about a case of Merkel cell carcinoma showing diffuse DLL3 (delta-like protein 3) expression?
DLL3 is under investigation as a potential biomarker for DLL3-targeting antibody-drug conjugates.
#IHCPath #MDACCPath #pathology
What about a case of Merkel cell carcinoma showing diffuse DLL3 (delta-like protein 3) expression?
DLL3 is under investigation as a potential biomarker for DLL3-targeting antibody-drug conjugates.
#IHCPath #MDACCPath #pathology
January 18, 2025 at 2:16 PM
New Year #dermpath special! 😆🔬
What about a case of Merkel cell carcinoma showing diffuse DLL3 (delta-like protein 3) expression?
DLL3 is under investigation as a potential biomarker for DLL3-targeting antibody-drug conjugates.
#IHCPath #MDACCPath #pathology
What about a case of Merkel cell carcinoma showing diffuse DLL3 (delta-like protein 3) expression?
DLL3 is under investigation as a potential biomarker for DLL3-targeting antibody-drug conjugates.
#IHCPath #MDACCPath #pathology